• Ajay Sanjay Salvi
• Mohini S.Khamkar
• Dr Lahu D.Hingane

Imeglimin is an investigational first‐in‐class novel oral agent for the treatment of type 2 diabetes. Imeglimin's mechanism of action involves two distinct effects: (a) an increase in glucose-stimulated insulin secretion (GSIS) and preservation of cell mass; and (b) an improvement in insulin action, with the potential to reduce hepatic glucose output and enhance insulin signaling in both the liver and skeletal muscle. Imeglimin may address mitochondrial dysfunction, a frequent underlying factor in the pathophysiology of T2D, at the cellular and molecular level. Reduced reactive oxygen species formation (decreasing oxidative stress) and prevention of mitochondrial permeability transition pore opening (implicated in preventing cell death) have been observed as a result of the observed rebalancing of respiratory chain activity (partial inhibition of Complex I and correction of deficient Complex III activity).

Type 2 diabetes, Imeglimin, Mechanism, Mitochondria.

"Development and Validation of RP-HPLC Method for Estimation of Anti-Diabetic Drug in Bulk and Tablet Dosage Form", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.10, Issue 5, page no.h366-h378, May-2023, Available :http://www.jetir.org/papers/JETIR2305743.pdf

"Development and Validation of RP-HPLC Method for Estimation of Anti-Diabetic Drug in Bulk and Tablet Dosage Form", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.10, Issue 5, page no. pph366-h378, May-2023, Available at : http://www.jetir.org/papers/JETIR2305743.pdf